BSB PHARMA
The computed 12-month bankruptcy probability of BSB PHARMA is 3.2% (moderate). The 2025 annual accounts show equity of €80k and a net result of €10k. Equity is growing by ~28.8% per year across the filed fiscal years. Its solvency ranks better than 82% of 1392 sector peers (fiscal year 2025). The company has been active since 2022 and the Belgian State Gazette contains no insolvency or warning signals.
| Equity | €80k |
| Net result | €10k |
| Better than sector | 82% |
| Active | 3 yrs |
Exceptional profile, strong across almost every axis.
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
Unlock the full score breakdown, per-year score history and the indicative credit limit with Plus.
See plans →How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 67.2% | 23.6% | |
| Net result | €10k | €8k | |
| Equity | €80k | €26k | |
| Gross operating margin | €51k | €35k | |
| Total assets | €119k | €133k |
| Fiscal year | 2025 |
|---|---|
| Revenue | - |
| EBITDA | €51k |
| Net profit | €10k |
| Cash flow | €10k |
| Staff costs | - |
| Income taxes | €3k |
| Dividends | €0 |
| Total assets | €119k |
| Equity | €80k |
| Debt | €39k |
| of which ≤ 1y | €39k |
| of which > 1y | - |
| Working capital | €80k |
| Employees (FTE) | - |
| 2025 | |
|---|---|
| Current ratio | 3.05 |
| Quick ratio | 3.05 |
| Working capital ratio | 67.1% |
| Solvency | 67.2% |
| Debt / equity | 0.49 |
| Long-term debt ratio | - |
| Interest coverage | 1.34 |
| Gross margin | - |
| Net margin | - |
| ROA | 8.1% |
| ROE | 12.1% |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | - |
| Inventory turnover | - |
| Days inventory (DSI) | - |
| Line item | Code | 2025 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €119k |
| Fixed assets | 21/28 | €75 |
| Tangible fixed assets | 22/27 | €75 |
| Current assets | 29/58 | €119k |
| Amounts receivable within one year | 40/41 | €7k |
| Cash & bank | 54/58 | €111k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €119k |
| Equity | 10/15 | €80k |
| Contributions / capital | 10/11 | €1k |
| Reserves | 13 | €69k |
| Accumulated profits (losses) | 14 | €10k |
| Amounts payable | 17/49 | €39k |
| Amounts payable within one year | 42/48 | €39k |
| Trade debts payable within one year | 44 | €0 |
| Income statement | ||
| Gross operating margin | 9900 | €51k |
| Operating result | 9901 | €51k |
| Financial charges | 65 | €38k |
| Result before taxes | 9903 | €13k |
| Income taxes | 67/77 | €3k |
| Net result for the period | 9904 | €10k |
| Result to be appropriated | 9905 | €10k |
| NACE primary | Retail trade(47730) |
| Legal form | Private limited company(610) |
| Incorporation | 07-10-2022 |
| Status | Active |
| Postal code | 1083 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 21392B0023/00Z006 | Brussels | 146 m² | - | - |
| 21007A0029/00G010 | Brussels | 80 m² | - | - |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
27-05-2026 General meeting · Seat change · Approval · Act object
- Filing: 2028-05-19 · BSB PHARMA
- General meeting: 2025-09-01 · BSB PHARMA
- Seat change: to: rue Georges Simpson 47 1083 Ganshoren, from: rue du croissant 86 1190 Forest, effective_date: 2025-09-01 · BSB PHARMA
- Approval: unanimité des voix · BSB PHARMA
- Publication: 2026-05-27
- Act object: Siège (transfert de siège)
Technical details
{
"facts": [
{
"type": "filing",
"quote": "D\u00E9pos\u00E9 / Re\u00E7u le 19 MAI 2028",
"value": "2028-05-19",
"object": null,
"subject": "e1"
},
{
"type": "general_meeting",
"quote": "Par d\u00E9lib\u00E9ration en date du 01/09/2025 l\u0027assembl\u00E9e g\u00E9n\u00E9rale a d\u00E9cid\u00E9 ce qui suit:",
"value": "2025-09-01",
"object": null,
"subject": "e1"
},
{
"type": "seat_change",
"quote": "L\u0027assembl\u00E9e d\u00E9cide que le si\u00E8ge de la soci\u00E9t\u00E9 sera transf\u00E9r\u00E9 de rue du croissant 86 1190 Forest \u00E0 rue Georges Simpson 47 1083 Ganshoren \u00E0 partir du 01/09/2025.",
"value": {
"to": "rue Georges Simpson 47 1083 Ganshoren",
"from": "rue du croissant 86 1190 Forest",
"effective_date": "2025-09-01"
},
"object": null,
"subject": "e1"
},
{
"type": "approval",
"quote": "Cette d\u00E9cision est prise \u00E0 la majorit\u00E9 suivante: unanimit\u00E9 des voix.",
"value": "unanimit\u00E9 des voix",
"object": null,
"subject": "e1"
},
{
"type": "publication",
"quote": "Belgisch Staatsblad - 27/05/2026",
"value": "2026-05-27",
"object": null,
"subject": null
},
{
"type": "act_object",
"quote": "Objet de l\u0027acte: Si\u00E8ge (transfert de si\u00E8ge)",
"value": "Si\u00E8ge (transfert de si\u00E8ge)",
"object": null,
"subject": null
}
],
"act_meta": {
"model_id": 40,
"extractor": "open-capture-27b-v3",
"ocr_chars": 1103,
"truncated": false,
"needs_verify": true
},
"entities": [
{
"id": "e1",
"kbo": "0792.204.443",
"kind": "company",
"name": "BSB PHARMA",
"attrs": {
"new_seat": "rue Georges Simpson 47 1083 Ganshoren",
"old_seat": "Rue du cassont 86 1190 Forest",
"legal_form": "SRL"
}
}
]
}11-10-2022 Incorporation of a new SRL
Technical details
{
"kind": "oprichting",
"seat": "1190 Forest, Rue du Croissant 86",
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"founders": [
{
"org": null,
"kind": "natural_person",
"person": {
"dob": "1993-03-26",
"name": "BEN SALEM Bassem",
"niss": null,
"address": "1190 Forest, rue du Croissant 86/0002"
},
"share_class": "Ordinary",
"partner_role": null,
"holder_org_kbo": null,
"holder_org_name": null,
"contribution_type": "cash",
"amount_paid_in_eur": 1300,
"holder_person_name": "BEN SALEM Bassem",
"is_subscriber_only": false,
"n_shares_subscribed": 100,
"amount_subscribed_eur": 1300,
"is_anonymous_silent_partner": false
}
],
"capital_eur": 1300,
"subject_company": {
"kbo": "0792.204.443",
"name_full": "BSB PHARMA",
"legal_form": "SRL"
},
"initial_directors": [],
"incorporation_date": "2022-10-06",
"post_incorporation_mandates": []
}Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
| Legal nameFR | BSB PHARMA |